The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors.
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson/Janssen; Kyowa Kirin; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Mitsuhiro Abe
No Relationships to Disclose
 
Kenta Murotani
Speakers' Bureau - Astrazeneca; Chugai Pharma; MSD; Nippon Shinyaku; Pfizer; Taiho pharmaceutical
 
Yuki Sato
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Janssen; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Regeneron
 
Takashi Kijima
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD
Research Funding - MSD
 
Motohiro Tamiya
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Pfizer
 
Yoshihiko Taniguchi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; MSD; Ono Pharmaceutical
 
Hidekazu Suzuki
Honoraria - AstraZeneca Canada; Chugai Pharma; MSD
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Yoshihiko Sakata
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Janssen Oncology; Novocure
Speakers' Bureau - Amgen; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Novartis; Novocure; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
 
Eri Takase
No Relationships to Disclose
 
Daisuke Arai
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ayumu Otsuki
No Relationships to Disclose
 
Teppei Yamaguchi
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Merck; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Jun Sugisaka
Honoraria - AstraZeneca; Kyowa Kirin International
 
Hiroshi Yokouchi
No Relationships to Disclose
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Kyowa Kirin International; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Mebix (Inst); Medpace (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Prime-R (Inst); Syneos Health (Inst)
 
Hiroaki Akamatsu
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Lilly; MSD; Nippon Kayaku; Novartis; Novocure; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Novartis (Inst)